Next Article in Journal
Cannabinoids Reduce Inflammation but Inhibit Lymphocyte Recovery in Murine Models of Bone Marrow Transplantation
Next Article in Special Issue
Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology
Previous Article in Journal
Skin Sensitization Testing—What’s Next?
Previous Article in Special Issue
Association of the MDM2 SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control Study
Open AccessReview

The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer

1
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 2010 Sydney, Australia
2
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, 2052 Sydney, Australia
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(3), 667; https://doi.org/10.3390/ijms20030667
Received: 16 December 2018 / Revised: 21 January 2019 / Accepted: 28 January 2019 / Published: 4 February 2019
(This article belongs to the Special Issue Molecular Biology and Pathology of Breast Cancer)
Basal-like breast cancer (BLBC) is an aggressive molecular subtype that represents up to 15% of breast cancers. It occurs in younger patients, and typically shows rapid development of locoregional and distant metastasis, resulting in a relatively high mortality rate. Its defining features are that it is positive for basal cytokeratins and, epidermal growth factor receptor and/or c-Kit. Problematically, it is typically negative for the estrogen receptor and human epidermal growth factor receptor 2 (HER2), which means that it is unsuitable for either hormone therapy or targeted HER2 therapy. As a result, there are few therapeutic options for BLBC, and a major priority is to define molecular subgroups of BLBC that could be targeted therapeutically. In this review, we focus on the highly proliferative and anti-apoptotic phenotype of BLBC with the goal of defining potential therapeutic avenues, which could take advantage of these aspects of tumor development. View Full-Text
Keywords: basal-like breast cancer; BLBC; triple-negative breast cancer; TNBC; targeted therapies; cell cycle; apoptosis basal-like breast cancer; BLBC; triple-negative breast cancer; TNBC; targeted therapies; cell cycle; apoptosis
Show Figures

Figure 1

MDPI and ACS Style

Alexandrou, S.; George, S.M.; Ormandy, C.J.; Lim, E.; Oakes, S.R.; Caldon, C.E. The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. Int. J. Mol. Sci. 2019, 20, 667.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop